Efficiency And Safety Of Association Arbutin, Triamcinolone And Tretinoin In The Treatment Of Facial Melasma, Taking As Reference The Product Triluma ® (Hidroquinone, Fluoncinolone And Tretinoin).

ATTGLE0508

The objective of this study is evaluating the clinical activity of the association (tretinoin + arbutin + triamcinolone) in the treatment of epidermal melasma.

2008-07-01

2008-07-01

2008-07-01

Early phase I

110

Inclusion Criteria: * Women adults aged more than 18 years; * Patients suffering from melasma Epidermal the face of mild and moderate; * Patients who have not done any treatment for melasma in the 3 months preceding the study; * Patients with good mental and physical health; * Patients who agree with the purposes of the study and sign the TCLE. Exclusion Criteria: * Patients with skin diseases other than melasma, which interfere in clinical evaluation as hemangiomas and queloides; * Patients with melasma skin or mixed; * Patients with sensitivity to agents hipopigmentantes; * Patients with sensitivity to fotoprotetores; * Patients who are pregnant or breastfeeding; * Patients who, at the discretion doctor, are not able to participate in the study; * Patients who have carried out any treatment for melasma in the 3 months preceding the study * Patients who do not agree with the terms described in the Statement of Informed Consent

{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2', 'PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}}, 'enrollmentInfo': {'count': 110, 'type': 'ESTIMATED'}}

2022-11-03